Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2011

Investigators Get $8M to Set Up Parkinson’s Brain Bank

  • The National Institute of Neurological Disorders and Stroke (NINDS) will give Banner Sun Health Research Institute (BSHRI) and Mayo Clinic Arizona an $8 million, five-year grant to support a "National Brain and Tissue Resource for Parkinson's Disease and Related Disorders."

    The NINDS award will fund studies of Arizonans with Parkinson disease as well as normal aging individuals. The researchers will collect information from clinical research testing on a yearly basis and perform autopsies to study the brain and other bodily tissue. Both brain tissue and related clinical data will be shared with 50 or more different research organizations throughout the world every year.

    A critical feature of this program is the confirmation of the clinical diagnosis through autopsy. One major goal of the funding is to find the earliest clinical markers for the onset of Parkinson disease and for the onset of dementia in people with Parkinson disease.

    Thomas Beach, M.D., Ph.D., of BSHRI, is principal investigator and heads the neuropathology operations for the project, while Charles Adler, M.D., Ph.D., of the Mayo Clinic, is co-investigator and directs the clinical aspects. Both are also currently co-principal investigators of the Arizona Parkinson's Disease Consortium.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »